Comparative recurrence rate investigation of esomeprazole versus lansoprazole in triple-combination therapy to eradicate Helicobacter pylori infection among pediatrics: multicentre, randomized, and controlled trials
Abstract
Background: Helicobacter pylori (H. pylori) infection contributes significantly to the steadily rising worldwide health burden. Due to oral and fecal-oral transmission pathways, its incidence is 50% worldwide and higher in younger individuals in underdeveloped nations. Most pediatric infections are asymptomatic or typically present as vague gastrointestinal symptoms such as persistent stomachache. Eradication therapy for H. pylori remains controversial. Only a small number of trials have compared esomeprazole with lansoprazole in children receiving triple combination therapy to eradicate H. pylori. Other treatments that have been used include bismuth, ranitidine, histamine-2 (H2) antagonists, proton pump inhibitors (PPI), and many antibiotics. This study aimed to assess the recurrence rates of esomeprazole and lansoprazole in triple combination therapy to eradicate H. pylori infection among Indonesian children.
Methods: Children (those between the 2–18) hospitalized throughout the research period and suspected of having an H. pylori infection are the subjects of our multicenter, double-blind, randomized investigation. SPSS was used to process the data at a significance level of p <0.05. The factors involved were analyzed using an analytical design. This study has been registered in ClinicalTrials.gov with a trial identification number NCT05861687.
Results: A total of 53 patients were eligible and met the inclusion and exclusion criteria. Four subjects were then excluded…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 53 participants or records.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.